Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
1.
Ann Surg Oncol ; 27(6): 2051-2060, 2020 Jun.
Article in English | MEDLINE | ID: mdl-31848813

ABSTRACT

PURPOSE: The benefit of adjuvant chemotherapy remains unknown for patients with stage IA micropapillary predominant (MPP) lung adenocarcinoma (ADC). This study investigated the effect of adjuvant chemotherapy in ADC and MPP patients in stage IA. METHODS: A total of 5220 stage IA lung ADC patients from SEER database and 152 MPP subtype patients from Qilu Hospital of Shandong University were retrospectively analyzed. Propensity score matching analysis was used to adjust the confounding factors. The benefits of improved overall survival (OS) or progression-free survival (PFS) from adjuvant chemotherapy in patients with resected stage IA ADC or MPP patients were investigated. RESULTS: Based on SEER database, for ADC patients in stage IA, chemotherapy (no vs. yes: hazard ratio [HR]: 0.674, 95% confidence interval [CI] 0.474-0.958, P = 0.030), together with radiotherapy (no vs. yes: HR: 0.519, 95% CI 0.358-0.751, P = 0.001), race, gender, age, and T stage were all statistically significant independent factors for OS. However, in propensity model, there was no significant difference in OS between patients who received adjuvant chemotherapy and those who did not. Only age was a significant prognostic predictor for OS. For patients with MPP subtype in stage IA, multivariate analysis revealed that chemotherapy (no vs. yes: HR: 2.054, 95% CI 1.085-3.886, P = 0.027) as well as T stage were prognostic predictors for OS. Chemotherapy (no vs. yes: HR: 2.205, 95% CI 1.118-4.349, P = 0.022) and T stage also were significant predictors for PFS. CONCLUSIONS: Adjuvant chemotherapy is a favorable prognostic factor for MPP patients in stage IA but not for lung ADC patients. MPP subtype could benefit from adjuvant chemotherapy.


Subject(s)
Adenocarcinoma, Papillary/drug therapy , Chemotherapy, Adjuvant/methods , Lung Neoplasms/drug therapy , Adenocarcinoma, Papillary/mortality , Adenocarcinoma, Papillary/pathology , Female , Humans , Lung Neoplasms/mortality , Lung Neoplasms/pathology , Male , Neoplasm Recurrence, Local/pathology , Neoplasm Staging , Prognosis , Propensity Score , Retrospective Studies , SEER Program , Survival Analysis , Treatment Outcome
2.
Med Sci Monit ; 21: 1138-45, 2015 Apr 21.
Article in English | MEDLINE | ID: mdl-25896429

ABSTRACT

BACKGROUND: Ketamine in subanesthetic dose added to butorphanol has been reported to give superior pain control when used for intravenous patient-controlled analgesia (PCA) after surgery. However, this admixture is not available commercially and stability data applicable to hospital practice are limited. MATERIAL/METHODS: The butorphanol-ketamine admixtures were prepared in polyolefin bags and stored in the dark at 4°C, 25°C, or 37°C for 15 days. The initial concentrations were 50-150 microgram/ml for butorphanol and 1-4 mg/ml for ketamine, respectively. The stabilities were determined by visual inspection, pH measurement, and high-pressure liquid chromatography (HPLC) assay of drug concentrations. RESULTS: Over the 15 days, all solutions were clear in appearance, and no color change or precipitation was observed among the three temperatures. The percentages of initial concentration of each drug were over 95% during the study period, and the pH value did not change significantly. CONCLUSIONS: The results indicate that the drug mixtures of butorphanol and ketamine in 0.9% sodium chloride injection were stable for 15 days when stored in polyolefin bags at 4°C, 25°C, or 37°C.


Subject(s)
Analgesia, Patient-Controlled , Analgesics/administration & dosage , Butorphanol/administration & dosage , Ketamine/administration & dosage , Analgesics/analysis , Butorphanol/analysis , Chromatography, High Pressure Liquid , Drug Stability , Drug Storage , Humans , Hydrogen-Ion Concentration , Infusions, Intravenous , Ketamine/analysis , Pain Management , Pain, Postoperative/drug therapy , Solutions , Temperature , Time Factors
3.
Front Pharmacol ; 15: 1247646, 2024.
Article in English | MEDLINE | ID: mdl-38384296

ABSTRACT

Objective: Patient-controlled intravenous analgesia (PCIA) can alleviate pain to some extent, and several randomized controlled trials (RCTs) have examined the efficacy of esketamine-assisted sufentanil in postoperative PCIA. In this research, we conducted a meta-analysis of relevant RCTs to compare the effect and safety of esketamine-sufentanil versus sufentanil alone for postoperative PCIA. Methods: We systematically searched the Cochrane Library, PubMed, Embase, Web of Science, CNKI, and other libraries up to December 2023 to screen out RCTs examining the use of esketamine combined with sufentanil for PCIA. We analysed analgesia scores, sedation scores, adverse drug reactions and postpartum depression scores as outcome indicators. Results: This meta-analysis included 32 RCTs. The results of the meta-analysis were as follows. 1) Visual Analog Scale: The VAS scores at 6, 12, 24, and 48 h were lower in the esketamine-sufentanil group than in the sufentanil alone group, and significant differences were found at all time points (p < 0.05). 2) Ramsay Sedation Scale: The sedation score of the esketamine-sufentanil group at 48 h after surgery was higher than that of the sufentanil group alone [mean difference (MD) = -0.09 points, confidence interval (CI): (-0.26, -0.07), p = 0.27], but this difference was not significant (p > 0.05). 3) Safety: Compared with sufentanil alone, the incidence rates of postoperative nausea-vomiting, dizziness-headache, skin pruritus and respiratory depression were significantly lower in the esketamine-sufentanil group. 4) Postartum depression: The reduction in postpartum depression scores were significantly greater in the esketamine-sufentanil group than in the sufentanil alone group at 3 days [MD = -1.35 points, CI: (-1.89, -0.81), p < 0.00001] and 7 days [MD = -1.29 points, CI: (-2.42, -0.16), p = 0.03]. Conclusion: The meta-analysis showed that the use of esketamine combined with sufentanil for postoperative PCIA could improve postoperative analgesia, alleviate postpartum depression and reduce the rate of postoperative adverse reactions, but there was no significant difference in sedation.

4.
BMC Chem ; 18(1): 10, 2024 Jan 10.
Article in English | MEDLINE | ID: mdl-38200560

ABSTRACT

A green, efficient, sensitive and accurate detection method by HPLC-DAD and LC-MS/MS was developed and validated for the quantification of morphine, hydromorphone, oxycodone, ketamine tramadol, dezocine, ropivacaine, remifentanil, butorphanol, bupivacaine, droperidol, fentanyl, lornoxicam and sufentanil. The 14 mixtures were chromatographed via HPLC-DAD method which employed 0.05 mol/L potassium dihydrogen phosphate solution-acetonitrile as the mobile phase, the analytes were gradient elution on a SinoChrom ODS-BP C18 column with a total separation time of 35 min, and 14 mixtures showed a good linear relationship in the linear range. The Limit of Quantitation (LOQ) ranged from 0.10 to 20.0 µg/mL, the inter-day and intra-day precision of each analyte is within 1.1-2.0% and 0.4-1.3%, and the average absolute recovery of all compounds was above 98%. The LC-MS/MS method was used to successfully separate the 14 mixtures within 10 min which employed 0.1% formic acid-acetonitrile as the mobile phase, the analytes were gradient elution on a ACQUITY UPLC-BEH C18 column with a total separation time of 13 min, and 14 mixtures showed a good linear relationship in the linear range. The LOQ ranged from 0.005 to 0.2 ng/mL, the inter-day and intra-day precision of each analyte is within 1.2-4.1% and 0.6-3.3%, and the average absolute recovery of all compounds was above 93%. The proposed method has been successfully applied in the clinic and provides a strong technical basis for the quantitative detection of these 14 mixtures for detecting drug abuse, and for studying the stability and compatibility of analgesic solutions. The proposed methods were validated against ICH guidelines.

5.
Article in English | MEDLINE | ID: mdl-34580594

ABSTRACT

Angina pectoris (AP) with coronary heart disease (CHD) is one of the common cardiovascular diseases in clinical practice, which can be classified as "chest paralysis" in Chinese medicine according to its symptoms, and it is described in many ancient documents. Ancient Chinese medicine believes that the main pathogenesis of the disease is poor blood flow leading to paralysis of the heart and veins, so it is often treated by activating blood and removing blood stasis. In this study, 120 patients with AP of CHD of Qi stagnation and blood stasis type were randomly divided into the observation (n = 60) and the control group (n = 60). In the control group, basic care, conventional treatment, and unselected copper acupuncture scraping were used, while in the observation group, copper acupuncture scraping was performed at the right time of the heart meridian (11 : 00-13 : 00) on the basis of the control group, and all patients received the treatment for a total duration of 4 weeks. We collected data on the traditional Chinese medical (TCM) syndrome score, frequency and duration of angina attacks, nitroglycerin dosage, inflammatory factor levels, and hematological indices pretreatment and posttreatment in both groups. Patients' adverse effects during treatment were recorded, and the clinical efficacy and ECG efficacy in both groups were evaluated after 4 weeks. We used SPSS.20 statistical software to statistically analyze the above data, and the results showed that the clinical efficacy and ECG efficacy of the observation group were significantly higher than the control group posttreatment. After treatment, the TCM symptom score, angina attack frequency, attack duration and nitroglycerin dosage, serum interleukin-8 (IL-8), hypersensitive C-reactive protein (hs-CRP), and tumor necrosis factor-α (TNF-α) levels, whole blood viscosity (WBV), plasma viscosity (PV), fibrinogen (FIB), and hematocrit (Hct) were significantly lower in both groups compared with those posttreatment. And the observation group showed a greater decrease when compared with the control group. The results also showed that the overall incidence of adverse reactions was lower in both groups during the treatment period. The above results indicate that while ensuring high safety, the copper stone based on theory of midnight-noon ebb-flow can more effectively improve the symptoms and inflammatory response of the body and reduce the viscosity of the blood in AP with CHD of Qi stagnation and blood stasis, and it has better therapeutic effects.

6.
Polymers (Basel) ; 10(7)2018 Jun 21.
Article in English | MEDLINE | ID: mdl-30960618

ABSTRACT

The thermal conductivity of flake graphite (FG) particulates reinforced high density polyethylene (HDPE) composites was systematically investigated under a special dispersion state of FG particles. The effects of particle size, weight filling ratio and proportion of various sizes were discussed in detail. A special composite (15 wt % 500 µm/10 wt % 200 µm/10 wt % 20 µm/5 wt % 2 µm FG + 60 wt % polyethylene (PE)) with a high thermal conductivity about 2.49 W/(m·K) was produced by combining the synergistic effect of several fillers. The component material size distribution was employed to analyze the effect of particle size. And scanning electron microscope (SEM) was adopted to observe the FG network in the composites. Thermogravimetric analysis (TGA) revealed the good thermal stability of composites. Differential scanning calorimetry (DSC) indicated that all composites own a similar melting temperature. Sample compression experiment indicated that all composites still exhibit high mechanical strength. Consequently, the easy-making flake graphite reinforced polyethylene composites with a high thermal conductivity would have a wide application in the new material field, such as a thermal interface material, a heat exchanger, voltage cable, etc.

7.
Biosci Trends ; 9(4): 237-44, 2015 Aug.
Article in English | MEDLINE | ID: mdl-26355225

ABSTRACT

Endothelial dysfunction is closely associated with hypertension. Protection of vascular endothelial cell is the key to prevention and treatment of hypertension. Uncaria rhynchophylla total alkaloids and Semen Raphani soluble alkaloid, isolated from traditional Chinese medicine Uncaria rbyncbopbylla and Semen Raphani respectively, exhibit properties of anti-hypertension and protection of blood vessels. In the present study, we observed the protective effect of the combined use of Uncaria rhynchophylla total alkaloids and Semen Raphani soluble alkaloid to the vascular endothelial cell in N'-nitro-L-arginine-induced hypertensive rats and investigate the preliminary mechanism. Blood pressure was detected by non-invasive rats tail method to observe the anti-hypertension effect of drugs. Scanning electron microscopy was used to observe the integrity or shedding state of vascular endothelial cell. The amount of circulating endothelial cells and CD54 and CD62P expression on circulating endothelial cells were tested to evaluate the endothelium function. In this study, we found that the Uncaria rhynchophylla total alkaloids and Semen Raphani soluble alkaloid compatibility can effectively lower the blood pressure, improve the structural integrity of vascular endothelium, and significantly reduce the number of circulating endothelial cells. Furthermore, the mean fluorescence intensity of CD54 and CD62P expressed showed decrease after the intervention of Uncaria rhynchophylla total alkaloids and Semen Raphani soluble alkaloid compatibility. In conclusion, the combination of effective components of the Uncaria rhynchophylla total alkaloids and Semen Raphani soluble alkaloid demonstrated good antihypertension effect and vascular endothelium protective effect. The preliminary mechanism of the protective effect may attribute to relieve the overall low-grade inflammation.


Subject(s)
Brassicaceae/chemistry , Cytoprotection/drug effects , Endothelial Cells/cytology , Hypertension/chemically induced , Hypertension/drug therapy , Protective Agents/therapeutic use , Uncaria/chemistry , Animals , Antigens, CD/metabolism , Blood Pressure/drug effects , Cell Count , Cell Shape/drug effects , Endothelial Cells/drug effects , Endothelial Cells/ultrastructure , Hypertension/physiopathology , Male , Nitroarginine , Phytotherapy , Protective Agents/pharmacology , Rats, Inbred WKY
8.
Medicine (Baltimore) ; 94(6): e432, 2015 Feb.
Article in English | MEDLINE | ID: mdl-25674732

ABSTRACT

Tropisetron is an adjuvant for butorphanol used in intravenous patient-controlled analgesia (PCA) and has been reported to provide superior pain control. It is efficacious in reducing the incidence of postoperative nausea and vomiting. However, this admixture is not available commercially and stability data applicable to hospital practice are limited. This study aimed to describe the drug compounding and evaluates the long-term (up to 14 days) stability of butorphanol and tropisetron in 0.9% sodium chloride injection for PCA use.In this study, commercial solutions of butorphanol tartrate and tropisetron hydrochloride were combined and further diluted with 0.9% sodium chloride injection to final concentrations of butorphanol tartrate 0.08 mg/mL and tropisetron hydrochloride 0.05 mg/mL. The polyolefin bags and glass bottles were stored at 4°C and 25°C for up to 14 days. The drug stabilities were determined by visual inspection, pH measurement, and high-pressure liquid chromatography assay of drug concentrations.The data obtained for admixtures prepared and stored at temperatures of 25°C and 4°C show the drugs have maintained at least 98% of the initial concentration. All solutions remained clear and colorless over the 14-day period, and the pH value did not change significantly.The results indicate that admixtures of butorphanol tartrate 0.08 mg/mL and tropisetron hydrochloride 0.05 mg/mL in 0.9% sodium chloride injection solution were stable for 14 days when stored in polyolefin bags or glass bottles at 4°C and 25°C and protected from light. The infusion is feasible for manufacturing in pharmacy aseptic units and can be stored for up to 14 days for routine use in PCA infusions.


Subject(s)
Analgesia, Patient-Controlled , Analgesics, Opioid/administration & dosage , Butorphanol/administration & dosage , Indoles/administration & dosage , Butorphanol/analysis , Chromatography, High Pressure Liquid , Drug Combinations , Drug Stability , Drug Storage/methods , Humans , Indoles/analysis , Infusions, Intravenous , Sodium Chloride , Tropisetron
9.
Am J Health Syst Pharm ; 70(6): 515-9, 2013 Mar 15.
Article in English | MEDLINE | ID: mdl-23456405

ABSTRACT

PURPOSE: The compatibility and stability of butorphanol tartrate and droperidol in polyvinyl chloride (PVC) bags and glass bottles stored at 4°C and 25°C for up to 15 days were studied. METHODS: Admixtures were assessed initially and for 15 days after preparation in PVC bags and glass bottles using 0.9% sodium chloride injection as a diluent and stored at 4°C and 25°C. The initial drug concentrations were 0.08 mg/mL for butorphanol tartrate and 0.05 mg/mL for droperidol. Samples were withdrawn from each container immediately after preparation and at predetermined intervals (2, 4, 8, 24, 48, 72, 120, 168, 240, and 360 hours after preparation). The solutions were visually inspected for precipitation, cloudiness, and discoloration at each sampling interval. Drug concentrations were determined using a validated high-pressure liquid chromatography method. RESULTS: After 15 days of storage, all formulations tested retained >98% of the initial concentrations of both drugs. The drug mixtures were clear in appearance, and no color change or precipitation was observed. Throughout this period, pH values remained stable. CONCLUSION: Admixtures of butorphanol tartrate 0.08 mg/mL and droperidol 0.05 mg/mL in 0.9% sodium chloride injection were stable for at least 360 hours when stored in PVC bags or glass bottles at 4°C and 25°C and protected from light.


Subject(s)
Butorphanol/standards , Droperidol/standards , Sodium Chloride/standards , Butorphanol/administration & dosage , Butorphanol/metabolism , Droperidol/administration & dosage , Droperidol/metabolism , Drug Interactions/physiology , Drug Stability , Drug Storage/methods , Drug Storage/standards , Injections, Intravenous , Pharmaceutical Solutions , Sodium Chloride/administration & dosage , Sodium Chloride/metabolism
10.
ACS Nano ; 7(5): 4070-81, 2013 May 28.
Article in English | MEDLINE | ID: mdl-23586816

ABSTRACT

A new graphene-fullerene composite (rGO-pyrene-PCBM), in which [6,6]-phenyl-C61-butyric acid methyl ester (PCBM) was attached onto reduced graphene oxide (rGO) via the noncovalent functionalization approach, was reported. The pyrene-PCBM moiety was synthesized via a facile esterification reaction, and pyrene was used as an anchoring bridge to link rGO and PCBM components. FTIR, UV-vis, and XPS spectroscopic characterizations were carried out to confirm the hybrid structure of rGO-pyrene-PCBM, and the composite formation is found to improve greatly the dispersity of rGO in DMF. The geometric configuration of rGO-pyrene-PCBM was studied by Raman, SEM, and AFM analyses, suggesting that the C60 moiety is far from the graphene sheet and is bridged with the graphene sheet via the pyrene anchor. Finally rGO-pyrene-PCBM was successfully applied as electron extraction layer for P3HT:PCBM bulk heterojunction polymer solar cell (BHJ-PSC) devices, affording a PCE of 3.89%, which is enhanced by ca. 15% compared to that of the reference device without electron extraction layer (3.39%). Contrarily, the comparative devices incorporating the rGO or pyrene-PCBM component as electron extraction layer showed dramatically decreased PCE, indicating the importance of composite formation between rGO and pyrene-PCBM components for its electron extraction property.

11.
Res Vet Sci ; 88(3): 446-51, 2010 Jun.
Article in English | MEDLINE | ID: mdl-20035963

ABSTRACT

Campylobacteriosis is a zoonosis that occurs worldwide. Infection with Campylobacter fetus (C. fetus) causes infertility and abortion in sheep and cattle. The current study focuses on the SapA gene of C. fetus that encodes surface array proteins and plays an important role in the virulence of C. fetus. The SapA-N (1398bp) and SapA-C (1422bp) fragments were amplified from the C. fetusSapA gene using polymerase chain reaction (PCR), and the corresponding recombinant proteins rSapA-N and rSapA-C were expressed in Escherichia. coli BL21 cells. Results of Western blotting and enzyme-linked immunosorbent assay (ELISA) showed that the immunological activity of rSapA-N was higher than that of rSapA-C (P<0.05). Therefore, rSapA-N was selected to establish an indirect ELISA for detecting antibodies against C. fetus. The diagnostic criteria were as follows: S/P0.45: positive; S/P<0.4: negative; 0.45>S/P0.4: suspected. The specificity and sensitivity of our method were 94.3% and 88.6%, respectively. Moreover, no cross-reactions were observed between rSapA-N and serum samples that were positive for other bovine bacterial pathogens diseases such as Mycobacterium avium subspecies paratuberculosis. One hundred and two serum samples from cows that had experienced abortion were tested. Four and 2 C. fetus-positive serum samples were found among the 70 bovine brucellosis-positive samples and the 32 infectious bovine rhinotracheitis (IBR)-positive samples, respectively. The findings suggest that the rSapA-N-based ELISA method has immense potential in future applications.


Subject(s)
Antibodies, Bacterial/analysis , Campylobacter Infections/veterinary , Campylobacter fetus/immunology , Cattle Diseases/microbiology , Enzyme-Linked Immunosorbent Assay/methods , Animals , Antigens, Bacterial/analysis , Antigens, Bacterial/genetics , Campylobacter Infections/blood , Campylobacter Infections/immunology , Campylobacter fetus/genetics , Cattle , Cattle Diseases/blood , Cattle Diseases/immunology , DNA Primers , DNA, Bacterial/genetics , DNA, Bacterial/isolation & purification , Dairying , Enzyme-Linked Immunosorbent Assay/veterinary , Female , Gene Amplification , Male , Polymerase Chain Reaction , Semen/microbiology , Vagina/microbiology
SELECTION OF CITATIONS
SEARCH DETAIL